Business Description
CStone Pharmaceuticals
ISIN : KYG2588M1006
Total Employee Number:
136Compare
Compare
Traded in other countries / regions
02616.Hong KongCSPHF.USAPH4.Germany Index Membership
Hong Kong Stock Connect IPO Date
2019-02-26Description
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.64 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | -0.85 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.82 | |||||
Beneish M-Score | -2.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -22.3 | |||||
3-Year EBITDA Growth Rate | 28.8 | |||||
3-Year EPS without NRI Growth Rate | 24.7 | |||||
3-Year FCF Growth Rate | 27.3 | |||||
3-Year Book Growth Rate | 3.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 76.12 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.2 | |||||
9-Day RSI | 55.23 | |||||
14-Day RSI | 54.79 | |||||
3-1 Month Momentum % | -42.29 | |||||
6-1 Month Momentum % | -23.48 | |||||
12-1 Month Momentum % | -48.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.18 | |||||
Quick Ratio | 1.95 | |||||
Cash Ratio | 1.8 | |||||
Days Inventory | 303.37 | |||||
Days Sales Outstanding | 79.95 | |||||
Days Payable | 344.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.2 | |||||
Shareholder Yield % | -9.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 19.41 | |||||
Operating Margin % | -154.11 | |||||
Net Margin % | -161.36 | |||||
EBITDA Margin % | -151.6 | |||||
FCF Margin % | -120.73 | |||||
OCF Margin % | -120.73 | |||||
ROE % | -101.74 | |||||
ROA % | -33.53 | |||||
ROIC % | -69.41 | |||||
3-Year ROIIC % | -249.42 | |||||
ROC (Joel Greenblatt) % | -384.66 | |||||
ROCE % | -58.38 | |||||
Moat Score | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 146.29 | |||||
PS Ratio | 24.73 | |||||
PB Ratio | 11.13 | |||||
Price-to-Tangible-Book | 14.63 | |||||
EV-to-EBIT | -17.47 | |||||
EV-to-EBITDA | -17.47 | |||||
EV-to-Revenue | 26.49 | |||||
EV-to-FCF | -21.94 | |||||
Price-to-GF-Value | 4.7 | |||||
| Price-to-Net-Current-Asset-Value | 18.29 | |||||
| Price-to-Net-Cash | 39.38 | |||||
Earnings Yield (Greenblatt) % | -5.72 | |||||
FCF Yield % | -4.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CStone Pharmaceuticals Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 297.238 | ||
| EPS (TTM) (HK$) | -0.34 | ||
| Beta | 1.3966 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.01 | ||
| Volatility % | 89.01 | ||
| 14-Day RSI | 54.79 | ||
| 14-Day ATR (HK$) | 0.362361 | ||
| 20-Day SMA (HK$) | 4.9655 | ||
| 12-1 Month Momentum % | -48.99 | ||
| 52-Week Range (HK$) | 4.01 - 13.15 | ||
| Shares Outstanding (Mil) | 1,594.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CStone Pharmaceuticals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CStone Pharmaceuticals Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-14 10:00 | 5.79 (-2.36%) | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 5.79 (-2.36%) | ||
| General meeting for 2025 | 2026-06-23 10:00 | 4.70 (+0.86%) | ||
| Annual report for 2025 | 2026-04-27 | 9.68 (-3.20%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-27 10:00 | 6.90 (+2.68%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 6.89 (+3.45%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-15 10:00 | 7.45 (+0.54%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 7.42 (+7.38%) | ||
| General meeting for 2024 | 2025-06-25 10:00 | 4.29 (+1.66%) | ||
| Annual report for 2024 | 2025-04-28 | 2.85 (-7.17%) |
Show
Entries
CStone Pharmaceuticals Frequently Asked Questions
What is CStone Pharmaceuticals(HKSE:02616)'s stock price today?
The current price of HKSE:02616 is HK$5.12. The 52 week high of HKSE:02616 is HK$13.15 and 52 week low is HK$4.01.
When is next earnings date of CStone Pharmaceuticals(HKSE:02616)?
The next earnings date of CStone Pharmaceuticals(HKSE:02616) is 2027-03-26 Est..
Does CStone Pharmaceuticals(HKSE:02616) pay dividends? If so, how much?
CStone Pharmaceuticals(HKSE:02616) does not pay dividend.
Press Release
Articles on CStone Pharmaceuticals
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers